Austin, Texas, September 9th, 2026, FinanceWire
Disseminated on behalf of Onco-Innovations Ltd. and may include paid advertising.
Investors in biotechnology often look for companies with a clear path toward clinical development, where regulatory preparation, manufacturing readiness and access to capital can help reduce execution risk. Onco-Innovations Ltd. is advancing ONC010, a nanoparticle-encapsulated PNKP inhibitor designed to target DNA repair pathways involved in cancer survival and treatment resistance. The company has strengthened its clinical foundation through manufacturing milestones, IND-enabling activities, strategic partnerships and a recent funding arrangement designed to support continued advancement of its oncology pipeline.For biotechnology investors, a clear path to the clinic can be one of the most important indicators of a company’s development potential. In oncology, where programs often face significant scientific, regulatory and financial hurdles, companies that demonstrate measurable progress across manufacturing, preclinical testing and operational execution may be better positioned to advance promising therapies.
One company working to advance this transition is Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) (FSE: W1H) , a preclinical-stage precision oncology company focused on developing therapies targeting…
Read More>>
NOTE TO INVESTORS: The latest news and updates relating to ONNVF are available in the company’s newsroom at https://nnw.fm/ONNVF
About NetworkNewsWire
NetworkNewsWire (“NNW”) is a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets ; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions . With broad reach and a seasoned team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled recognition and brand awareness. NNW is where breaking news, insightful content and actionable information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: https://www.NetworkNewsWire.com/Disclaimer
NetworkNewsWire
Austin, Texas
www.NetworkNewsWire.com
512.354.7000 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is powered by IBN
Contact
IBNwww.InvestorBrandNetwork.com
Editor@InvestorBrandNetwork.com